The non-canonical NF-kappaB Signaling Pathway Contributes to the Expansion and Lymphomagenesis of CD40-activated B Cells
Authors: Kuhn Laura Bernhardine , Zapf Stefanie , Kristina Djermanovic , Strobl Daniel C. , Weih Falk , Blum Helmut , Weigert Oliver , Strobl Lothar J. , Ursula Zimber-Strobl 
Published: October 2019

The non-canonical NF-κB pathway is highly conserved, can be activated by TNF-receptors e.g. CD40 and is dysregulated in several lymphomas (Krappmann and Vincendeau 2016). In human DLBCL hyper-activation of the non-canonical NF-kB signaling pathway could be detected in about 15% (Zhang et al. 2015). Upon activation of the non-canonical NF-κB pathway RelB is translocated to the nucleus and acts as transcription factor. RelB is important to maintain viability of a Hodgkin Lymphoma cell line (Ranuncolo et al. 2012), but interestingly B cell specific inactivation of RelB in mature B cells of transgenic mice have only a minor effect on B cell maintenance and activation (De Silva et al. 2016). Therefore it is still elusive, whether RelB-regulated genes contribute to lymphoma development.

To study the contribution of RelB-regulated genes to lymphoma development we used a mouse model expressing a constitutively active CD40 receptor in B cells (LMP1/CD40stopflmice). LMP1/CD40 is a fusion protein comprising the signaling domain of human CD40 and the transmembrane domain of LMP1 and promotes a persistently activation of CD40 signaling. In LMP1/CD40stopfl//CD19-Cre (LMP1/CD40) mice the constitutive CD40 activation leads to the selective activation of the non-canonical NF-kB pathway and the MAP kinase pathways JNK and ERK. LMP1/CD40-expression positively affects cell survival and proliferation of B cells resulting in a B cell expansion and accumulation of B cells in follicles of young mice. Mice older than 12 months develop lymphomas with a high incidence. In most cases the lymphoma was monoclonal and had the phenotype B220low, CD21- and CD23- (Hojer et al. 2014; Hömig-Hölzel et al. 2008). Recently, we observed that this aberrant population appears at around 6 months of age and increases continuously during the aging process.

To unveil the contribution of the non-canonical NF-κB pathway to the phenotype and lymphoma development of constitutively CD40-activated B cells we crossed conditional RelBfl/fl mice to LMP1/CD40stopfl//CD19-Cre mice (RelBKO//LMP1/CD40 mice). In young mice we were able to observe that LMP1/CD40 B cells without functional RelB were less expanded in the spleen and lymph nodes, but had elevated B cell numbers in the blood and a higher number of recirculating B cells in the bone marrow. This indicates that RelB-regulated genes are important for the retention of CD40-activated B cells in B cell follicles of secondary lymphoid organs. In addition, the survival of ex vivo isolated LMP1/CD40-expressing RelB-deficient B cells was diminished in comparison to LMP1/CD40-expressing RelB-proficent B cells, but RelBKO//LMP1/CD40 B cells still survived better than control B cells. Furthermore, we found that RelBKO//LMP1/CD40 B cells were less activated than LMP1/CD40 B cells, but had a higher expression of the tested activation markers than control B cells.

In order to characterize the influence of RelB-regulated genes on lymphoma development in LMP1/CD40 mice we analyzed LMP1/CD40-expressing mice at different time points. The aberrant population, arising in LMP1/CD40 mice, was also detectable in aged RelBKO//LMP1/CD40 mice, though showed a delayed progression and always had a lower expansion than in age-matched LMP1/CD40 mice. Both transgenic mice developed monoclonal lymphomas. However, the double mutant mice had a lower tumor incidence than LMP1/CD40 mice with functional RelB. Nevertheless, the risk of lymphoma development in RelBKO//LMP1/CD40 was still higher than in wildtype mice.

In the last part of this study we performed a RNA-Seq. analysis to see which genes are RelB-dependent in chronically CD40-activated B cells. We identified several RelB-dependent genes and 21 of these had been correlated with Non-Hodgkin Lymphoma. Some of these candidates could be promising new therapy targets and are under further investigation.

In conclusion we provide evidence that RelB-regulated genes contribute to the survival and activation of B cells, which are chronically activated by CD40 signaling. Furthermore, we found that CD40 signaling enhances the retention of B cells in B cell follicles through activation of the non-canonical NF-kB pathway. Moreover, we demonstrated that RelB-regulated genes contribute to B cell lymphomagenesis and identified several RelB-regulated genes that may contribute to the expansion and lymphomagenesis of B cells receiving a chronic CD40 signal.

Disclosures

Weigert: Roche: Research Funding; Novartis: Research Funding.